Vident Advisory LLC Sells 21,835 Shares of Cencora, Inc. (NYSE:COR)

Vident Advisory LLC lessened its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 80.8% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 5,199 shares of the company's stock after selling 21,835 shares during the period. Vident Advisory LLC's holdings in Cencora were worth $1,168,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Triglav Skladi D.O.O. bought a new stake in Cencora during the 4th quarter worth about $3,640,000. Twinbeech Capital LP acquired a new position in shares of Cencora during the fourth quarter worth approximately $12,929,000. Tidal Investments LLC grew its stake in shares of Cencora by 3.1% during the fourth quarter. Tidal Investments LLC now owns 21,319 shares of the company's stock valued at $4,790,000 after purchasing an additional 635 shares during the last quarter. Strategic Wealth Partners Ltd. increased its holdings in shares of Cencora by 34.2% in the fourth quarter. Strategic Wealth Partners Ltd. now owns 31,749 shares of the company's stock valued at $7,763,000 after purchasing an additional 8,092 shares in the last quarter. Finally, Toronto Dominion Bank raised its position in Cencora by 3.5% in the 4th quarter. Toronto Dominion Bank now owns 70,905 shares of the company's stock worth $15,929,000 after purchasing an additional 2,408 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Trading Up 0.3%

Shares of NYSE COR traded up $0.87 during midday trading on Tuesday, reaching $293.22. 1,241,488 shares of the stock were exchanged, compared to its average volume of 1,545,066. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $309.35. The company has a market capitalization of $56.83 billion, a price-to-earnings ratio of 41.71, a P/E/G ratio of 1.31 and a beta of 0.60. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The business has a 50-day simple moving average of $282.95 and a two-hundred day simple moving average of $257.50.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The firm had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. During the same period in the previous year, the company posted $3.80 earnings per share. The company's revenue for the quarter was up 10.3% on a year-over-year basis. As a group, equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Investors of record on Friday, May 16th will be paid a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. Cencora's payout ratio is 25.52%.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Morgan Stanley set a $288.00 price objective on Cencora in a research report on Tuesday, April 15th. UBS Group upped their target price on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Citigroup raised their target price on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, Robert W. Baird boosted their price target on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $301.18.

Insiders Place Their Bets

In related news, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $255.00, for a total value of $1,267,350.00. Following the sale, the chief executive officer now owns 51,070 shares of the company's stock, valued at approximately $13,022,850. This trade represents a 8.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This trade represents a 9.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 45,223 shares of company stock worth $12,369,767. Company insiders own 10.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.